Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles-Reference-Cited by-同舟云学术

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles

Published:2020-08-09 Issue:3 Volume:87 Page:1243-1252
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Thorén Linda¹²^ORCID,Lindh Jonatan D.³,Ackehed Gerd³,Kringen Marianne Kristiansen⁴⁵,Hall Per⁶,Bergh Jonas⁷,Molden Espen⁴⁸^ORCID,Margolin Sara¹²,Eliasson Erik³

Affiliation:

1. Department of Clinical Science and Education at Södersjukhuset Karolinska Institutet Stockholm Sweden

2. Department of Oncology South General Hospital Stockholm Sweden

3. Department of Laboratory Medicine, Clinical Pharmacology Karolinska Institutet and Karolinska University Hospital Stockholm Sweden

4. Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway

5. Department of Life Sciences and Health Oslo Metropolitan University Oslo Norway

6. Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden

7. Department of Oncology‐Pathology, Karolinska Institutet and Breast Cancer Center, Cancer Theme Karolinska University Hospital Stockholm Sweden

8. Department of Pharmaceutical Biosciences, School of Pharmacy University of Oslo Oslo Norway

Funder

Stockholms Läns Landsting

Cancerfonden

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14500

Reference39 articles.

1. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

3. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

4. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

5. Update on Allele Nomenclature for Human Cytochromes P450 and the Human Cytochrome P450 Allele (CYP-Allele) Nomenclature Database

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype–phenotype translation;Basic & Clinical Pharmacology & Toxicology;2023-06-04

2. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer;Clinical Pharmacology & Therapeutics;2023-04-28

3. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records;Breast Cancer Research and Treatment;2023-03-01

4. Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen;Journal of Personalized Medicine;2023-01-31

5. Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study;Journal of Oncology Pharmacy Practice;2022-12-25